Clinical trials: Chronic Myeloid Leukemia (CML)
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Chronic Myeloid Leukemia
Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia
Fludarabine, cyclophosphamide, and rituximab (FCR) is the gold treatment for fit and young patients with Chronic Lymphoid Leukemia (CLL).
- Trial name
- VeRitAs (NCT03455517)
- Testing
- Venetoclax, Rituximab
- Where
- 31 sites in Italy
- Volunteers
- 77 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Hematologic Malignancies, Bone Marrow Transplant Rejection
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added back.
- Trial name
- NCT00079391
- Testing
- allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Background: One way to treat certain cancers of the blood and immune system is to give a patient stem cells from the bone marrow of a donor whose genes are very similar but not identical to the patients.
- Conditions
- Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01338987
- Testing
- First Allogeneic Bone Marrow Transplant (BMT), Leuprolide, 18F FLT
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects of dasatinib in treating patients with chronic myelogenous…
- Trial name
- NCT00345826
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Chronic Phase of Chronic Myeloid Leukemia
Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase
Interferon alpha was a therapy used in Chronic Myeloid Leukemia in Chronic phase prior to the advent of tyrosine kinase inhibitors.
- Trial name
- NCT01872442
- Testing
- Dasatinib, Peg-Interferon alpha2b
- Sponsor
- Poitiers University Hospital
Chronic Myelogenous Leukemia
Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias
This is a two-part safety and efficacy study of SKI-606 in subjects who have Philadelphia chromosome positive leukemias (CML). Part 1 will be a dose-escalation study, in which an escalating dose of SKI-606 (Bosutinib), up to 600…
- Trial name
- NCT00811070
- Testing
- SKI-606 (Bosutinib)
- Where
- 23 sites in Japan
- Volunteers
- 63 people
- Sponsor
- Pfizer
Chronic Myeloid Leukaemia
Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
The GIMEMA CML Working Party promotes an observational (retrospective and perspective) study of Imatinib-resistant or intolerant CML patients treated with Nilotinib in Italy.
- Trial name
- CML0609 (NCT01475110)
- Testing
- Imatinib
- Where
- 33 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia, Myeloid, Chronic-Phase
Study in Patients With Chronic Leukemia
This study will include patients suffering from chronic myeloid leukemia (CP-CML), who were treated with tyrosine kinase inhibitor (TKI, a substance that blocks the action of enzymes) in a previous therapy but which has not been…
- Trial name
- PONS (NCT03807479)
- Testing
- Ponatinib
- Where
- 10 sites in Germany
- Volunteers
- 18 people
- Sponsor
- GWT-TUD GmbH
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes
- Trial name
- NCT00005797
- Testing
- busulfan, Cyclophosphamide, VP-16
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, Myelodysplastic Syndromes
Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00002890
- Testing
- lintuzumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Nilotinib Pre and Post Allogeneic Stem Cell Transplantation
Current therapeutic results in advanced chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) are rather disappointing. Most of these patients will eventually undergo allogeneic stem cell transplantation.
- Conditions
- Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Stem Cell Transplantation
- Trial name
- NCT00750659
- Testing
- Nilotinib
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Sheba Medical Center
Chronic Myeloid Leukemia
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
The purpose of this study is to evaluate complete molecular response of Dasatinib in patients for Philadelphia chromosome-positive chronic myeloid leukemia
- Trial name
- CMR-CML (NCT01342679)
- Testing
- dasatinib
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Kanto CML Study Group
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This pilot phase I trial studies the side effects of engineered donor stem cell transplant in treating patients with hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia
- Trial name
- NCT02960646
- Testing
- Cyclophosphamide, Filgrastim, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
The goal of this clinical study is to gain essential insights into the relationship between Tyrosine kinase inhibitor (TKI) therapy and profound fatigue and abnormal sleep patterns using rest-activity monitoring (actigraphy) and…
- Conditions
- Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase, Fatigue, Sleep Disturbance
- Trial name
- TIRE (NCT06233890)
- Testing
- Motion watch
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Imperial College Healthcare NHS Trust
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00096096
- Testing
- mycophenolate mofetil, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Myeloid Leukemia, Chronic
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
The objective is to evaluate the cytogenetic response to Dasatinib (BMS-354825) administered for 24 weeks in subjects with Imatinib resistant or intolerant chronic phase chronic myeloid leukemia (CML) once daily (QD) or twice…
- Trial name
- NCT00482703
- Testing
- Dasatinib
- Where
- 9 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Lymphoma
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
RATIONALE: Giving total-body irradiation and chemotherapy, such as cyclophosphamide, before a donor stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells and helps stop the growth of…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00317785
- Testing
- cyclophosphamide, cyclosporine, methotrexate
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloid Leukemia
Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism
- Trial name
- NCT07413263
- Testing
- Tyrosine kinase Inhibitors (Imatinib & Nilotinib)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, imatinib or nilotinib, work in treating patients with chronic myeloid leukemia.
- Trial name
- NCT03654768
- Testing
- Bosutinib, Dasatinib, Laboratory Biomarker Analysis
- Where
- 541 sites in United States
- Volunteers
- 81 people
- Sponsor
- SWOG Cancer Research Network